123 related articles for article (PubMed ID: 14501379)
21. Antitumor effects of analogs of LH-RH and somatostatin: experimental and clinical studies.
Schally AV; Srkalovic G; Szende B; Redding TW; Janaky T; Juhasz A; Korkut E; Cai RZ; Szepeshazi K; Radulovic S
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1061-7. PubMed ID: 1981009
[TBL] [Abstract][Full Text] [Related]
22. Antiproliferative efficacy of the somatostatin analogue TT-232 in human melanoma cells and tumours.
Schwab RE; Froidevaux S; Paku S; Tejeda M; Szende B; Pap A; Beglinger C; Eberle AN; Kéri G
Anticancer Res; 2001; 21(1A):71-5. PubMed ID: 11299792
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the antitumor efficacy of the somatostatin structural derivative TT-232 on different tumor models.
Tejeda M; Gaál D; Hullán L; Hegymegi-Barakonyi B; Kéri G
Anticancer Res; 2006; 26(5A):3477-83. PubMed ID: 17094470
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.
Nagy A; Schally AV; Halmos G; Armatis P; Cai RZ; Csernus V; Kovács M; Koppán M; Szepesházi K; Kahán Z
Proc Natl Acad Sci U S A; 1998 Feb; 95(4):1794-9. PubMed ID: 9465096
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis is induced in both drug-sensitive and multidrug-resistant hepatoma cells by somatostatin analogue TT-232.
Diaconu CC; Szathmári M; Kéri G; Venetianer A
Br J Cancer; 1999 Jun; 80(8):1197-203. PubMed ID: 10376972
[TBL] [Abstract][Full Text] [Related]
26. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin analogs and prednisone in advanced refractory thymic tumors.
Palmieri G; Montella L; Martignetti A; Muto P; Di Vizio D; De Chiara A; Lastoria S
Cancer; 2002 Mar; 94(5):1414-20. PubMed ID: 11920496
[TBL] [Abstract][Full Text] [Related]
28. In vivo antitumor activity of TT-232 a novel somatostatin analog.
Tejeda M; Gaal D; Schwab RE; Pap A; Keri G
Anticancer Res; 1999; 19(4B):3265-8. PubMed ID: 10652622
[TBL] [Abstract][Full Text] [Related]
29. The antitumour effect of the somatostatin analogue TT-232 depends on the treatment regimen.
Tejeda M; Gaál D; Csuka O; Ullrich A; Schwab R; Pap A; Horváth A; Kéri G
Cancer Detect Prev; 2003; 27(2):155-62. PubMed ID: 12670528
[TBL] [Abstract][Full Text] [Related]
30. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters.
Szepeshazi K; Lapis K; Schally AV
Int J Cancer; 1991 Sep; 49(2):260-6. PubMed ID: 1679045
[TBL] [Abstract][Full Text] [Related]
31. Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogs.
Imam H; Eriksson B; Lukinius A; Janson ET; Lindgren PG; Wilander E; Oberg K
Acta Oncol; 1997; 36(6):607-14. PubMed ID: 9408151
[TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors.
Pelton JT; Kazmierski W; Gulya K; Yamamura HI; Hruby VJ
J Med Chem; 1986 Nov; 29(11):2370-5. PubMed ID: 2878079
[TBL] [Abstract][Full Text] [Related]
33. The antitumor somatostatin analogue TT-232 induces cell cycle arrest through PKCdelta and c-Src.
Steták A; Lankenau A; Vántus T; Csermely P; Ullrich A; Kéri G
Biochem Biophys Res Commun; 2001 Jul; 285(2):483-8. PubMed ID: 11444868
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
Liebow C; Reilly C; Serrano M; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(6):2003-7. PubMed ID: 2564678
[TBL] [Abstract][Full Text] [Related]
35. Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan.
Rivier J; Erchegyi J; Hoeger C; Miller C; Low W; Wenger S; Waser B; Schaer JC; Reubi JC
J Med Chem; 2003 Dec; 46(26):5579-86. PubMed ID: 14667212
[TBL] [Abstract][Full Text] [Related]
36. Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8.
Erchegyi J; Penke B; Simon L; Michaelson S; Wenger S; Waser B; Cescato R; Schaer JC; Reubi JC; Rivier J
J Med Chem; 2003 Dec; 46(26):5587-96. PubMed ID: 14667213
[TBL] [Abstract][Full Text] [Related]
37. Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin.
Szende B; Zalatnai A; Schally AV
Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1643-7. PubMed ID: 2564204
[TBL] [Abstract][Full Text] [Related]
38. De novo design, synthesis, and pharmacology of alpha-melanocyte stimulating hormone analogues derived from somatostatin by a hybrid approach.
Han G; Haskell-Luevano C; Kendall L; Bonner G; Hadley ME; Cone RD; Hruby VJ
J Med Chem; 2004 Mar; 47(6):1514-26. PubMed ID: 14998337
[TBL] [Abstract][Full Text] [Related]
39. Effect of the gastrin-releasing peptide antagonist BIM 26226 and lanreotide on an acinar pancreatic carcinoma.
Damgé C; Hajri A
Eur J Pharmacol; 1998 Apr; 347(1):77-86. PubMed ID: 9650851
[TBL] [Abstract][Full Text] [Related]
40. Analgesic effect of TT-232, a heptapeptide somatostatin analogue, in acute pain models of the rat and the mouse and in streptozotocin-induced diabetic mechanical allodynia.
Szolcsányi J; Bölcskei K; Szabó A; Pintér E; Petho G; Elekes K; Börzsei R; Almási R; Szuts T; Kéri G; Helyes Z
Eur J Pharmacol; 2004 Sep; 498(1-3):103-9. PubMed ID: 15363982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
